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site for lead placement was thought to result in better
synchronization and outcomes.
As compared to the conventional site of LV pacing using
anatomic guide, the speckle-tracking guided pacing resulted
in a higher responder rates both in terms of LV size regression
and clinical end-points such as NYHA class and combined all-
cause mortality and heart failure hospitalizations.
However this study has many limitations: (1) speckle-
tracking radial strain imaging is neither the best nor the
final word in locating the last activation of LV; (2) small sample
sizewith limited follow-up of 6months fromonly 2 centres; (3)
so-far all echocardiographic studies to guide CRT has had
significant inter-observer variability and could not predict
outcomes (PROSPECT). Echo studies using advanced software
lack reproducibility, requires trained personnel and not
readily available for mass practical implementation; (4) in
almost one-third patients the targeted site could not be paced
because of inaccessible venous anatomy and or presence
of scar.
Nonetheless this study is a step-forward in establishing the
fact that if we can identify & pace the “sweet-spot” in the LV,
the responder rates can be improved.
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Context: The benefit of aspirin for the primary prevention
of cardiovascular events is relatively small for individuals
with and without diabetes. This benefit could easily be offset
by the risk of hemorrhage.
Objective: To determine the incidence of major gastroin-
testinal and intracranial bleeding episodes in individuals with
and without diabetes taking aspirin.
Design, setting, and participants: A population-based
cohort study, using administrative data from 4.1 million citi-
zens in 12 local health authorities in Puglia, Italy. Individuals
with new prescriptions for low-dose aspirin (300 mg) were
identified during the index period from January 1, 2003, to
December 31, 2008, and were propensity-matched on a 1-to-1
basis with individuals who did not take aspirin during this
period.
Main outcome measures: Hospitalizations for major
gastrointestinal bleeding or cerebral hemorrhage occurring
after the initiation of antiplatelet therapy.
Results: There were 186,425 individuals being treated with
low-dose aspirin and 186,425 matched controls without
aspirin use. During amedian follow-up of 5.7 years, the overall
incidence rate of hemorrhagic events was 5.58 (95% CI,
5.39e5.77) per 1000 person-years for aspirin users and 3.60
(95% CI, 3.48e3.72) per 1000 person-years for those withoutaspirin use (incidence rate ratio [IRR], 1.55; 95% CI, 1.48e1.63).
The use of aspirin was associated with a greater risk of major
bleeding in most of the subgroups investigated but not in
individuals with diabetes (IRR, 1.09; 95% CI, 0.97e1.22). Irre-
spective of aspirin use, diabeteswas independently associated
with an increased risk of major bleeding episodes (IRR, 1.36;
95% CI, 1.28e1.44).
Comments
In a population-based cohort, aspirin use was significantly
associated with an increased risk of major gastrointestinal or
cerebral bleeding episodes. Patients with diabetes had a high
rate of bleeding that was not independently associated with
aspirin use.
A meta-analysis based on individual patient data demon-
strated that the benefits of low-dose aspirin for the primary
prevention of cardiovascular disease are modest. Any benefit
of low-dose aspirin might be offset by the risk of major
bleeding. It is known that aspirin is associated with gastro-
intestinal and intracranial hemorrhagic complications.
Observational studies suggest an excess of approximately 1e2
major bleeding episodes annually for every 1000 patients
treated with low doses of aspirin. The bleeding risk sharply
increases in individuals older than 70 years. The bleeding rate
was five times higher than the bleeding rate expected based
on the results of previously published randomized clinical
trials. Diabetics had 36% increased risk of major bleeding
episodes irrespective of aspirin use. So, when we have to
balance the risk and benefits of aspirin, we have to remember
that the baseline risk of bleeding can be very high in some
subgroups of patients.
But this study, for the first time, to our knowledge, showed
that aspirin therapy only marginally increases the risk of
bleeding in individuals with diabetes. The incidence rate of
major bleeding was 5.35 per 1000 person-years in those who
never took aspirin compared with 5.83 among those taking
low-dose aspirin, a nonsignificant difference.
These results can represent indirect evidence that the
efficacy of aspirin in suppressing platelet function is reduced
in this population. An accelerated platelet turnover in dia-
betes could explain the reduced incidence of adverse effects
related to aspirin, as well as its limited efficacy in preventing
major cardiovascular events.
So finally, weighing the benefits of aspirin therapy against
the potential harms is of particular relevance in the primary
prevention setting, in which benefits seem to be lower than
expected based on results in high-risk populations. In this
population-based cohort, aspirin use was significantly asso-
ciated with an increased risk of major bleeding, but this
association was not observed for patients with diabetes. In
this respect, diabetes might represent a different population
in terms of both expected benefits and risks associated with
antiplatelet therapy.
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